



Published in final edited form as:

*Drug Dev Res.* 2019 August ; 80(5): 617–628. doi:10.1002/ddr.21539.

## Further modifications of 1H-pyrrolo[2,3-b]pyridine derivatives as inhibitors of human neutrophil elastase

Maria Paola Giovannoni<sup>a</sup>, Niccolò Cantini<sup>a</sup>, Letizia Crocetti<sup>a,\*</sup>, Gabriella Guerrini<sup>a</sup>, Antonella Iacovone<sup>a</sup>, Igor A. Schepetkin<sup>b</sup>, Claudia Vergelli<sup>a</sup>, Andrei I. Khlebnikov<sup>c,d</sup>, Mark T. Quinn<sup>b</sup>

<sup>a</sup>NEUROFARBA, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.

<sup>b</sup>Department of Microbiology and Immunology, Montana State University, Bozeman, MT 59717, USA.

<sup>c</sup>Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia.

<sup>d</sup>Scientific Research Institute of Biological Medicine, Altai State University, Barnaul 656049, Russia.

### Abstract

Human neutrophil elastase (HNE) is a potent protease that plays an important physiological role in many processes and is considered to be a multifunctional enzyme. HNE is also involved in a variety of pathologies affecting the respiratory system. Thus, compounds able to inhibit HNE proteolytic activity could represent effective therapeutics. We present here a new series of pyrrolo[2,3-b]pyridine derivatives of our previously reported potent HNE inhibitors. Our results show that position 2 of the pyrrolo[2,3-b]pyridine scaffold must be unsubstituted, and modifications of this position resulted in loss of HNE inhibitory activity. Conversely, the introduction of certain substituents at position 5 was tolerated, with retention of HNE inhibitory activity ( $IC_{50} = 15\text{--}51$  nM) after most substitutions, indicating that bulky and/or lipophilic substituents at position 5 probably interact with the large pocket of the enzyme site and allow Michaelis complex formation. The possibility of Michaelis complex formation between Ser195 and the ligand carbonyl group was assessed by molecular docking, and it was found that highly active HNE inhibitors are characterized by geometries favorable for Michaelis complex formation and by relatively short lengths of the proton transfer channel via the catalytic triad.

### Keywords

Pyrrolo[2,3-b]pyridine; human neutrophil elastase inhibitors; molecular docking

---

\*Corresponding Author Letizia Crocetti, Dipartimento di NEUROFARBA, Via Ugo Schiff 6, Sesto Fiorentino 50019 Firenze, Tel +39-055-4573683, letizia.crocetti@unifi.it.

## INTRODUCTION

Polymorphonuclear neutrophils represent a large percentage of the circulating leukocyte population and are the most abundant type of white blood cells in human blood. They are also known as granulocytes due to the numerous granules present in their cytoplasm and are characterized by their nuclear morphology, which is segmented into three to five lobes joined together by a thin membrane. These cells play a fundamental role in immune defense against pathogenic organisms and are the first mediators in the inflammatory response [Korkmaz et al., 2010]. Neutrophil granules are classified into primary or azurophil, secondary or specific, tertiary or gelatinase, and secretory [Pham, 2006]. Specifically, the azurophil granules contain myeloperoxidase, some bactericidal proteins, and three serine proteases: proteinase 3, cathepsin G, and human neutrophil elastase (HNE), which is a globular glycoprotein of about 30 kDa belonging to the chymotrypsin family. HNE consists of a single polypeptide chain of 218 amino acids, with two asparagine-linked carbohydrate side chains at Asn95 and Asn144 [Lucas et al., 2011]. HNE is stabilized by four disulfide bridges and has 19 arginine residues, resulting in an isoelectric point of 10–11. As with other neutrophil serine proteases, HNE plays an important physiological role and is considered a multifunctional enzyme that contributes to killing of pathogens, inflammatory processes, and maintenance of tissue homeostasis [Pham, 2006]. HNE proteolytic activity depends on the catalytic triad consisting of Ser195-His57-Asp102 [Fujinaga et al., 1996].

The proteolytic activity of serine proteases, which is essential for the maintenance of important host functions, can also be harmful if not properly regulated, and a number of regulatory mechanisms are present [Von Nussbaum et al., 2016]. For example, these proteases are stored as inactive precursors in specialized compartments, such as azurophil granules for serine proteases. Once active, serine protease activity can be regulated by endogenous inhibitors, such as  $\alpha$ 1-antitrypsin [also known as  $\alpha$ 1-proteinase inhibitor ( $\alpha$ 1-PI)], elafin, and secretory leukocyte protease inhibitor, which inhibit protease activity [Zhong et al., 2017; Von Nussbaum et al., 2015]. The involvement of HNE and other neutrophil serine proteases in the development of chronic pulmonary inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), acute lung injury, acute respiratory distress syndrome (ARDS), and cystic fibrosis (CF) is widely documented and correlated with an imbalance between HNE and endogenous inhibitor activity [Polverino et al., 2017].

Recently, we identified and characterized a number of potent HNE inhibitors with differing structural scaffolds [Schepetkin et al., 2007; Crocetti et al., 2011; Crocetti et al., 2013; Giovannoni et al., 2016; Crocetti et al., 2016; Vergelli et al., 2017; Giovannoni et al., 2018; Crocetti et al., 2018]. In the most recent studies, we identified HNE inhibitors with a pyrrolo[2,3-b]pyridine scaffold [Crocetti et al., 2018] and found that the most potent compounds exhibited  $IC_{50}$  values in the low nanomolar range (14–87 nM) (see Figure 1). Based on these studies, we performed further modifications of the pyrrolo[2,3-b]pyridine scaffold. While keeping the best substituents identified for N-1 (m-toluoyl) and position 3 (CN group), we introduced substituents with different features at position 5 to screen for more potent HNE inhibitors. Additionally, we investigated substitutions at position 2 of the scaffold by shifting CN from the 3 to the 2 position or inserting other groups.

## MATERIALS AND METHODS

### Chemistry

All final compounds were synthesized as reported in Figures 2-4, and the structures were confirmed on the basis of analytical and spectral data. To obtain the 2- or 2,3-disubstituted pyrrolo[2,3-b]pyridines (**2a-e**), we followed the procedures shown in Figure 2. Starting from the previously synthesized compounds **1a-e** [Sandham et al., 2009; Pires et al., 2016; Baltus et al., 2016; Bahekar et al., 2007], we performed benzylation with *m*-toluoyl chloride and triethylamine in anhydrous dichloromethane, resulting in final compounds **2a-e**. The synthesis of compounds with different substitutions at position 5 is shown in Figures 3 and 4. Figure 3 shows the synthesis of pyrrolo[2,3-b]pyridines substituted with a bromine, chlorine, or nitro group at position 5. The formyl group of intermediates **4a-c** [Xi and Li, 2014; Nirogi et al., 2012; Ermoli et al., 2009], obtained starting from the corresponding 5-substituted-pyrrolo[2,3-b]pyridines **3a-c** [Joydev et al., 2017; Chen et al., 2015; Bhat et al., 2015] by the Duff reaction, was transformed into the corresponding oxime by treatment with hydroxylamine hydrochloride and NaHCO<sub>3</sub> at high temperature, resulting in compounds **5a-c** [**5b**, Bahekar et al., 2007]. Further reaction with POCl<sub>3</sub> resulted in the 3-carbonitrile derivatives **6a-c** [**6a**, Graczyk et al., 2004], which were benzyolated at position 1 with *m*-toluoyl chloride and sodium hydride in anhydrous tetrahydrofuran to obtain the 5-substituted pyrrolo[2,3-b]pyridines **7a-c** (Figure 3).

Figure 4 shows the synthetic steps for insertion of (hetero)aromatic rings at position 5 to obtain final compounds **14a-g**. In the first step, the nitrogen at position 1 of intermediate **3a** [Joydev et al., 2017] was protected with benzenesulfonyl chloride to obtain compound **8** [Liu et al., 2016], which subsequently was treated with tetrakis(triphenylphosphine)palladium(0), 2M sodium carbonate solution, and the appropriate boronic acid in hot anhydrous toluene to obtain the corresponding 5-pyrrolo[2,3-b]pyridine derivatives **9a-g**. The protecting group at position N-1 was then removed with tetrabutylammonium fluoride (TBAF) in hot anhydrous tetrahydrofuran, resulting in pyrrolo[2,3-b]pyridines **10a-g** [**10a**, Laha et al., 2017; **10c** and **10d**, Ibrahim et al., 2007; **10f** and **10g**, Singh et al., 2017]. Reaction of these compounds with hexamethylenetetramine (HMTA) in acetic acid at reflux resulted in the 3-formyl derivatives **11a-g** [**11g**, Ibrahim et al., 2007], which, when treated with hydroxylamine hydrochloride (**12a-g**), dehydrated with POCl<sub>3</sub> (**13a-g**), and benzyolated at position 1 with *m*-toluoyl chloride, led to final compounds **14a-g**.

### Experimental

All melting points were determined on a Büchi apparatus (New Castle, DE) and are uncorrected. Extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvents were removed under reduced pressure. Merck F-254 commercial plates (Merck, Durham, NC) were used for analytical TLC to follow the course of reactions. Silica gel 60 (Merck 70–230 mesh, Merck, Durham, NC) was used for column chromatography. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on an Avance 400 instrument (Bruker Biospin Version 002 with SGU, Bruker Inc., Billerica, MA). Chemical shifts (δ) are reported in ppm to the nearest 0.01 ppm using the solvent as an internal standard. Coupling constants (J values) are given in Hz and were calculated using TopSpin 1.3 software (Nicolet Instrument Corp., Madison, WI) and are

rounded to the nearest 0.1 vHz. Mass spectra ( $m/z$ ) were recorded on an ESI-TOF mass spectrometer (Bruker Micro TOF, Bruker Inc., Billerica, MA), and reported mass values are within the error limits of  $\pm 5$  ppm mass units. Microanalyses indicated by the symbols of the elements were performed with a Perkin–Elmer 260 elemental analyzer (PerkinElmer, Inc., Waltham, MA) for C, H, and N, and the results were within  $\pm 0.4\%$  of the theoretical values, unless otherwise stated. Reagents and starting materials were commercially available.

### General procedure for compounds 2a-e.

To a cooled ( $0^{\circ}\text{C}$ ) suspension of the appropriate substrate **1a-e** [Sandham et al., 2009; Pires et al., 2016; Baltus et al., 2016; Bahekar et al., 2007] (0.56 mmol) in anhydrous  $\text{CH}_2\text{Cl}_2$  (2 mL), 0.72 mmol of  $\text{Et}_3\text{N}$ , and 1.67 mmol of *m*-toluoyl chloride were added. The mixture was stirred at  $0^{\circ}\text{C}$  for 2 h and then at room temperature for an additional 2 h. The solvent was evaporated, cold water was added, and the mixture was neutralized with 0.5 N NaOH. The reaction mixture was extracted with  $\text{CH}_2\text{Cl}_2$  ( $3 \times 15$  mL), and the solvent was dried over sodium sulfate and evaporated in vacuum. The final compounds **2a-e** were purified by column chromatography using toluene/ethyl acetate 9.5:0.5 (for **2a,b**) or cyclohexane/ethyl acetate 2:1 (for **2c,d**) or 5:1 (for **2e**) as eluents.

**(2-Methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)(*m*-tolyl)methanone (2a).**—Yield = 67%; oil.  $^1\text{H-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  2.39 (s, 3H, *m*- $\text{CH}_3\text{-Ph}$ ), 2.56 (s, 3H,  $\text{CH}_3$ ), 7.02–7.07 (m, 1H, Ar), 6.38 (s, 1H, Ar), 7.30 (t, 1H, Ar,  $J = 8.0$  Hz), 7.41 (d, 1H, Ar,  $J = 8.0$  Hz), 7.50 (d, 1H, Ar,  $J = 8.0$  Hz), 7.66 (s, 1H, Ar), 7.76 (d, 1H, Ar,  $J = 8.0$  Hz), 8.05 (d, 1H, Ar,  $J = 4.4$  Hz).  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  15.15 ( $\text{CH}_3$ ), 21.33 ( $\text{CH}_3$ ), 104.52 (CH), 117.37 (CH), 121.44 (C), 127.52 (CH), 128.04 (CH), 128.16 (CH), 131.13 (CH), 134.19 (CH), 134.77 (C), 138.16 (C), 138.90 (C), 142.62 (CH), 149.53 (C), 169.70 (CO). ESI-MS calcd. for  $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}$ , 250.30; found:  $m/z$  251.11  $[\text{M}+\text{H}]^+$ . Anal.  $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}$  (C, H, N).

**(2-Ethyl-1H-pyrrolo[2,3-b]pyridin-1-yl)(*m*-tolyl)methanone (2b).**—Yield = 17%; oil.  $^1\text{H-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  1.30 (t, 3H,  $\text{CH}_2\text{CH}_3$ ,  $J = 7.2$  Hz), 2.39 (s, 3H, *m*- $\text{CH}_3\text{-Ph}$ ), 2.98 (q, 2H,  $\text{CH}_2\text{CH}_3$ ,  $J = 7.2$  Hz), 6.43 (s, 1H, Ar), 7.03–7.08 (m, 1H, Ar), 7.30 (t, 1H, Ar,  $J = 7.6$  Hz), 7.41 (d, 1H, Ar,  $J = 7.6$  Hz), 7.49 (d, 1H, Ar,  $J = 7.6$  Hz), 7.66 (s, 1H, Ar), 7.78 (d, 1H, Ar,  $J = 7.6$  Hz), 8.05 (d, 1H, Ar,  $J = 4.4$  Hz).  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  12.82 ( $\text{CH}_3$ ), 21.44 ( $\text{CH}_3$ ), 21.81 ( $\text{CH}_2$ ), 102.58 (CH), 118.02 (CH), 121.33 (C), 128.08 (CH), 129.30 (CH), 131.13 (CH), 134.29 (CH), 134.78 (C), 138.20 (C), 142.76 (CH), 145.09 (C), 149.74 (C), 169.93 (CO). ESI-MS calcd. for  $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}$ , 264.32; found:  $m/z$  265.13  $[\text{M}+\text{H}]^+$ . Anal.  $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}$  (C, H, N).

**Ethyl 1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (2c).**—Yield = 34%; oil.  $^1\text{H-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  1.45 (t, 3H,  $\text{OCH}_2\text{CH}_3$ ,  $J = 7.2$  Hz), 2.38 (s, 3H, *m*- $\text{CH}_3\text{-Ph}$ ), 4.21 (q, 2H,  $\text{OCH}_2\text{CH}_3$ ,  $J = 7.2$  Hz), 7.16–7.21 (m, 1H, Ar), 7.29–7.34 (m, 2H, Ar), 7.42 (d, 1H, Ar,  $J = 7.6$  Hz), 7.56 (d, 1H, Ar,  $J = 7.6$  Hz), 7.71 (s, 1H, Ar), 8.04 (d, 1H, Ar,  $J = 8.0$  Hz), 8.41 (d, 1H, Ar,  $J = 4.4$  Hz).  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  13.94 ( $\text{CH}_3$ ), 21.29 ( $\text{CH}_3$ ), 61.59 ( $\text{CH}_2$ ), 111.04 (CH), 118.64 (CH), 119.46 (C), 127.93 (CH), 128.56 (CH), 130.65 (C), 131.02 (CH), 131.18 (CH), 134.03 (C), 135.01 (CH), 138.61 (C), 147.70 (CH),

150.05 (C), 160.65 (C), 169.00 (CO). ESI-MS calcd. for  $C_{18}H_{16}N_2O_3$ , 308.34; found:  $m/z$  309.12  $[M+H]^+$ . Anal.  $C_{18}H_{16}N_2O_3$  (C, H, N).

**1-(3-Methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile (2d).**—Yield = 41%; oil.  $^1H$ -NMR ( $CDCl_3-d_1$ )  $\delta$  2.41 (s, 3H, m- $CH_3$ -Ph), 7.25–7.33 (m, 1H, Ar), 7.34–7.40 (m, 2H, Ar), 7.48 (d, 1H, Ar,  $J=7.6$  Hz), 7.58 (d, 1H, Ar,  $J=7.6$  Hz), 7.69 (s, 1H, Ar), 8.03 (dd, 1H, Ar,  $J=8.0$  Hz and  $J=1.2$  Hz), 8.38 (d, 1H, Ar,  $J=3.6$  Hz).  $^{13}C$ -NMR ( $CDCl_3-d_1$ )  $\delta$  21.53 ( $CH_3$ ), 110.31 (C), 112.22 (C), 118.23 (CH), 119.60 (C), 120.03 (CH), 128.32 (CH), 128.59 (CH), 131.13 (CH), 131.61 (CH), 132.56 (C), 135.23 (CH), 138.52 (C), 148.37 (CH), 166.85 (CO). ESI-MS calcd. for  $C_{16}H_{11}N_3O$ , 261.28; found:  $m/z$  262.09  $[M+H]^+$ . Anal.  $C_{16}H_{11}N_3O$  (C, H, N).

**2-Methyl-1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (2e).**—Yield = 10%; oil.  $^1H$ -NMR ( $CDCl_3-d_1$ )  $\delta$  2.40 (s, 3H, m- $CH_3$ -Ph), 2.74 (s, 3H,  $CH_3$ ), 7.21–7.26 (m, 1H, Ar), 7.35 (d, 1H, Ar), 7.48 (d, 2H, Ar,  $J=7.6$  Hz), 7.64 (s, 1H, Ar), 7.98 (d, 1H, Ar,  $J=7.2$  Hz), 8.19 (d, 1H, Ar,  $J=4.0$  Hz).  $^{13}C$ -NMR ( $CDCl_3-d_1$ )  $\delta$  9.43 ( $CH_3$ ), 20.91 ( $CH_3$ ), 101.37 (C), 115.65 (CH), 115.92 (C), 121.15 (CH), 128.10 (CH), 128.36 (CH), 129.14 (CH), 130.17 (CH), 130.49 (CH), 134.86 (CH), 137.33 (C), 138.91 (C), 142.4 (CH), 146.36 (C), 167.70 (CO). ESI-MS calcd. for  $C_{17}H_{13}N_3O$ , 275.30; found:  $m/z$  276.11  $[M+H]^+$ . Anal.  $C_{17}H_{13}N_3O$  (C, H, N).

#### General procedure for compounds 5a and 5c.

A mixture of the appropriate 1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde **4a** [Xi and Li, 2014] or **4c** [Ermoli et al., 2009] (0.78 mmol) and hydroxylamine hydrochloride (2.35 mmol) in 2 mL of water was heated at 60°C for 30 min.  $NaHCO_3$  (2.35 mmol) was then added, and the reaction mixture was heated under reflux for 4 h at 100°C. After cooling at room temperature, the solid was filtered, washed with the excess of ice-cold water and dried. The crude product was recrystallized from hexane to obtain the pure product.

**(E)-5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (5a).**—Yield = 94%; mp = 235–237°C (hexane).  $^1H$ -NMR ( $DMSO-d_6$ )  $\delta$  7.81 (s, 1H,  $CH=N-OH$ ), 8.21 (s, 1H, Ar), 8.33 (s, 1H, Ar), 8.38 (s, 1H, Ar), 10.75 (exch br s, 1H,  $CH=N-OH$ ), 12.16 (exch br s, 1H, NH). ESI-MS calcd. for  $C_8H_6BrN_3O$ , 240.06; found:  $m/z$  240.97  $[M+H]^+$ . Anal.  $C_8H_6BrN_3O$  (C, H, N).

**(E)-5-Nitro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (5c).**—Yield = 40%; mp = 193–195°C (hexane).  $^1H$ -NMR ( $DMSO-d_6$ )  $\delta$  8.00 (s, 1H, Ar), 8.27 (s, 1H,  $CH=N-OH$ ), 9.04 (s, 1H, Ar), 9.13 (s, 1H, Ar), 11.02 (exch br s, 1H,  $CH=N-OH$ ), 12.70 (exch br s, 1H, NH). ESI-MS calcd. for  $C_8H_6N_4O_3$ , 206.16; found:  $m/z$  207.05  $[M+H]^+$ . Anal.  $C_8H_6N_4O_3$  (C, H, N).

#### General procedure for compounds 6b and 6c.

A suspension of intermediate **5b** [Bahekar et al., 2007] or **5c** (0.92 mmol) in 4 mL of  $POCl_3$  was stirred at reflux for 2 h. After cooling, ice-cold water (20 mL) was slowly added, and

the precipitate was filtered under vacuum and washed with abundant cold water to obtain the desired compound, which was recrystallized from ethanol.

**5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (6b).**—Yield = 90%; mp = 291–294°C (EtOH). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 8.27 (d, 1H, Ar, *J* = 2.0 Hz), 8.40 (d, 1H, Ar, *J* = 2.4 Hz), 8.51 (d, 1H, Ar, *J* = 3.2 Hz), 13.05 (exch br s, 1H, NH). IR ν (cm<sup>-1</sup>): 2240 (CN). ESI-MS calcd. for C<sub>8</sub>H<sub>4</sub>ClN<sub>3</sub>, 177.59; found: *m/z* 179.01 [M+H]<sup>+</sup>. Anal. C<sub>8</sub>H<sub>4</sub>ClN<sub>3</sub> (C, H, N).

**5-Nitro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (6c).**—Yield = 81%; mp = 248–250°C (EtOH). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 8.71 (s, 1H, Ar), 8.91 (s, 1H, Ar), 9.21 (s, 1H, Ar), 13.56 (exch br s, 1H, NH). IR ν (cm<sup>-1</sup>): 2220 (CN). ESI-MS calcd. for C<sub>8</sub>H<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 188.14; found: *m/z* 189.04 [M+H]<sup>+</sup>. Anal. C<sub>8</sub>H<sub>4</sub>N<sub>4</sub>O<sub>2</sub> (C, H, N).

### General procedure for compounds 7a-c.

To a suspension of the substrate **6a-c** [6a, Graczyk et al., 2004] (0.53 mmol) in 10 mL of anhydrous THF, 1.06 mmol of sodium hydride and 0.64 mmol of *m*-toluoyl chloride were added. The mixture was stirred at room temperature overnight. The solvent was concentrated *in vacuo* to obtain a residue that was purified by column chromatography using cyclohexane/ethyl acetate 6:1 (for **7a,b**) or 5:1 (for **7c**) as eluents.

**5-Bromo-1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (7a).**—Yield = 30%; mp = 156–159°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 2.44 (s, 3H, *m*-CH<sub>3</sub>-Ph), 7.41 (t, 1H, Ar, *J* = 7.6 Hz), 7.50–7.55 (m, 2H, Ar), 7.62 (s, 1H, Ar), 8.20–8.25 (m, 2H, Ar), 8.46 (s, 1H, Ar). <sup>13</sup>C-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 21.52 (CH<sub>3</sub>), 90.31 (C), 127.78 (CH), 128.67 (CH), 131.11 (CH), 131.77 (C), 135.21 (CH), 136.23 (CH), 138.87 (C), 145.41 (C), 166.46 (CO). IR ν (cm<sup>-1</sup>): 2224 (CN). ESI-MS calcd. for C<sub>16</sub>H<sub>10</sub>BrN<sub>3</sub>O, 340.17; found: *m/z* 341.00 [M+H]<sup>+</sup>. Anal. C<sub>16</sub>H<sub>10</sub>BrN<sub>3</sub>O (C, H, N).

**5-Chloro-1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (7b).**—Yield = 10%; mp = 150–152°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 2.44 (s, 3H, *m*-CH<sub>3</sub>-Ph), 7.41 (t, 1H, Ar, *J* = 7.2 Hz), 7.50–7.55 (m, 2H, Ar), 7.62 (s, 1H, Ar), 8.10 (s, 1H, Ar), 8.24 (s, 1H, Ar), 8.38 (s, 1H, Ar). <sup>13</sup>C-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 21.32 (CH<sub>3</sub>), 112.77 (C), 127.79 (CH), 127.96 (CH), 128.48 (CH), 128.71 (C), 130.99 (CH), 131.01 (C), 135.06 (CH), 136.04 (CH), 138.82 (C), 145.11 (C), 145.63 (CH), 166.33 (CO). IR ν (cm<sup>-1</sup>): 2223 (CN). ESI-MS calcd. for C<sub>16</sub>H<sub>10</sub>ClN<sub>3</sub>O, 295.72; found: *m/z* 297.05 [M+H]<sup>+</sup>. Anal. C<sub>16</sub>H<sub>10</sub>ClN<sub>3</sub>O (C, H, N).

**1-(3-Methylbenzoyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (7c).**—Yield = 35%; mp = 152–154°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 2.45 (s, 3H, *m*-CH<sub>3</sub>-Ph), 7.43 (t, 1H, Ar, *J* = 7.6 Hz), 7.55 (d, 2H, Ar, *J* = 7.6 Hz), 7.64 (s, 1H, Ar), 8.43 (s, 1H, Ar), 8.96 (d, 1H, Ar, *J* = 2.4 Hz), 9.27 (d, 1H, Ar, *J* = 2.4 Hz). <sup>13</sup>C-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 20.93 (CH<sub>3</sub>), 101.34 (C), 115.51 (C), 122.13 (C), 123.68 (CH), 128.16 (CH), 129.19 (CH), 130.42 (C), 130.57 (CH), 131.62 (C), 134.11 (CH), 137.65 (CH), 138.94 (C), 152.78 (C), 167.74 (CO). IR ν (cm<sup>-1</sup>): 2220 (CN). ESI-MS calcd. for C<sub>16</sub>H<sub>10</sub>N<sub>4</sub>O<sub>3</sub>, 306.28; found: *m/z* 307.08 [M+H]<sup>+</sup>. Anal. C<sub>16</sub>H<sub>10</sub>N<sub>4</sub>O<sub>3</sub> (C, H, N).

**General procedure for compounds 9a-g.**

To a suspension of intermediate **8** [Liu et al., 2016] (0.34 mmol) in 3 mL of toluene, 0.051 mmol of tetrakis(triphenylphosphine)palladium(0), 3 mL of Na<sub>2</sub>CO<sub>3</sub> 2M solution, and 0.68 mmol of the appropriate hetero(phenyl)-boronic acid were added. The mixture was stirred at reflux for 4 h. After cooling, ice-cold water (20 mL) was added, the suspension was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL), dried over sodium sulfate, and the solvent was evaporated *in vacuo* to obtain compounds **9a-g**, which were purified by column chromatography using hexane/ethyl acetate 3:1 (for **9b,e**), hexane/acetone 4:1 (for **9a,c,d,f**), or cyclohexane/ethyl acetate 1:5 (for **9g**) as eluents.

**5-Phenyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (9a).**—Yield = 79%; mp = 123–125°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 6.63 (d, 1H, Ar, *J* = 4.0 Hz), 7.36 (t, 1H, Ar, *J* = 7.2 Hz), 7.42–7.49 (m, 4H, Ar), 7.52–7.57 (m, 3H, Ar), 7.75 (d, 1H, Ar, *J* = 4.0 Hz), 7.98 (d, 1H, Ar, *J* = 2.0 Hz), 8.22 (d, 2H, Ar, *J* = 7.2 Hz), 8.65 (d, 1H, Ar, *J* = 2.0 Hz). ESI-MS calcd. for C<sub>19</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S, 334.39; found: *m/z* 335.08 [M+H]<sup>+</sup>. Anal. C<sub>19</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S (C, H, N).

**1-(Phenylsulfonyl)-5-(3-(trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridine (9b).**—Yield = 79%; mp = 145–148°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 6.66 (d, 1H, Ar, *J* = 4.0 Hz), 7.50 (t, 2H, Ar, *J* = 8.0 Hz), 7.56–7.61 (m, 2H, Ar), 7.63 (d, 1H, Ar, *J* = 7.6 Hz), 7.72 (d, 1H, Ar, *J* = 7.6 Hz), 7.78 (d, 2H, Ar, *J* = 4.0 Hz), 8.02 (d, 1H, Ar, *J* = 2.0 Hz), 8.22 (d, 2H, Ar, *J* = 7.2 Hz), 8.63 (d, 1H, Ar, *J* = 2.0 Hz). ESI-MS calcd. for C<sub>20</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S, 402.39; found: *m/z* 403.07 [M+H]<sup>+</sup>. Anal. C<sub>20</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S (C, H, N).

**1-(Phenylsulfonyl)-5-(*m*-tolyl)-1H-pyrrolo[2,3-b]pyridine (9c).**—Yield = 78%; mp = 140–143°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 2.41 (s, 3H, *m*-CH<sub>3</sub>-Ph), 6.63 (d, 1H, Ar, *J* = 4.0 Hz), 7.19 (s, 1H, Ar), 7.30–7.35 (m, 3H, Ar), 7.48 (t, 1H, Ar, *J* = 8.0 Hz), 7.56 (t, 2H, Ar, *J* = 7.6 Hz), 7.75 (d, 1H, Ar, *J* = 4.0 Hz), 7.98 (d, 1H, Ar, *J* = 2.0 Hz), 8.22 (d, 2H, Ar, *J* = 7.6 Hz), 8.64 (d, 1H, Ar, *J* = 2.0 Hz). ESI-MS calcd. for C<sub>20</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S, 348.42; found: *m/z* 349.10 [M+H]<sup>+</sup>. Anal. C<sub>20</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S (C, H, N).

**5-(3-Methoxyphenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (9d).**—Yield = 78%; mp = 106–109°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 3.85 (s, 3H, OCH<sub>3</sub>), 6.64 (d, 1H, Ar, *J* = 4.0 Hz), 6.92 (dd, 1H, Ar, *J* = 2.0 Hz and *J* = 8.4 Hz), 7.07 (s, 1H, Ar), 7.12 (d, 1H, Ar, *J* = 7.6 Hz), 7.37 (t, 1H, Ar, *J* = 7.6 Hz), 7.50 (t, 2H, Ar, *J* = 8.0 Hz), 7.58 (t, 1H, Ar, *J* = 7.6 Hz), 7.75 (d, 1H, Ar, *J* = 4.0 Hz), 8.00 (d, 1H, Ar, *J* = 2.0 Hz), 8.22 (d, 2H, Ar, *J* = 7.6 Hz), 8.65 (d, 1H, Ar, *J* = 2.0 Hz). ESI-MS calcd. for C<sub>20</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S, 364.42; found: *m/z* 365.09 [M+H]<sup>+</sup>. Anal. C<sub>20</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S (C, H, N).

**5-(6-Methoxynaphthalen-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (9e).**—Yield = 91%; mp = 173–176°C dec. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 3.93 (s, 3H, OCH<sub>3</sub>), 6.65 (d, 1H, Ar, *J* = 3.6 Hz), 7.15–7.21 (m, 2H, Ar), 7.49 (t, 2H, Ar, *J* = 8.0 Hz), 7.56 (d, 1H, Ar, *J* = 7.2 Hz), 7.64 (d, 1H, Ar, *J* = 8.0 Hz), 7.75–7.83 (m, 3H, Ar), 7.92 (s, 1H, Ar), 8.08 (s, 1H, Ar), 8.24 (d, 2H, Ar, *J* = 7.6 Hz), 8.75 (s, 1H, Ar). ESI-MS calcd. for C<sub>24</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>S, 414.48; found: *m/z* 415.11 [M+H]<sup>+</sup>. Anal. C<sub>24</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>S (C, H, N).

**1-(Phenylsulfonyl)-5-(thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridine (9f).**—Yield = 55%; mp = 186–189°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 6.59–6.63 (m, 1H, Ar), 7.22–7.27 (m, 1H, Ar), 7.35–7.50 (m, 4H, Ar), 7.53–7.58 (m, 1H, Ar), 7.70–7.75 (m, 1H, Ar), 8.00 (s, 1H, Ar), 8.18–8.23 (m, 2H, Ar), 8.68 (s, 1H, Ar). ESI-MS calcd. for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub>, 340.43; found: *m/z* 341.04 [M+H]<sup>+</sup>. Anal. C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> (C, H, N).

**1-(Phenylsulfonyl)-5-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine (9g).**—Yield = 98%; mp = 148–152°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 6.68 (d, 1H, Ar, *J* = 3.6 Hz), 7.49–7.62 (m, 4H, Ar), 7.82 (s, 1H, Ar), 8.03 (s, 2H, Ar), 8.23 (d, 2H, Ar, *J* = 7.6 Hz), 8.62–8.67 (m, 2H, Ar), 8.85 (s, 1H, Ar). ESI-MS calcd. for C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>S, 335.38; found: *m/z* 336.08 [M+H]<sup>+</sup>. Anal. C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>S (C, H, N).

### General procedure for compounds 10b and 10e.

To a solution of intermediate **9b** or **9e** (0.29 mmol) in anhydrous THF (3 mL), 0.87 mmol of TBAF was added, and the mixture was stirred at reflux for 4 h. After cooling, the solvent was evaporated, and cold-ice water (20 mL) was added. The precipitate was recovered by vacuum filtration and purified by crystallization from ethanol to obtain the desired compound **10b** or by column chromatography using cyclohexane/ethyl acetate 1:1 as eluent for **10e**.

**5-(3-(Trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridine (10b).**—Yield = 97%; mp = 158–161°C (EtOH). <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 6.65 (d, 1H, Ar, *J* = 3.2 Hz), 7.47 (d, 1H, Ar, *J* = 3.2 Hz), 7.59–7.67 (m, 2H, Ar), 7.80 (d, 1H, Ar, *J* = 7.2 Hz), 7.86 (s, 1H, Ar), 8.27 (d, 1H, Ar, *J* = 1.2 Hz), 8.54 (s, 1H, Ar), 10.12 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>14</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>, 262.23; found: *m/z* 263.08 [M+H]<sup>+</sup>. Anal. C<sub>14</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub> (C, H, N).

**5-(6-Methoxynaphthalen-2-yl)-1H-pyrrolo[2,3-b]pyridine (10e).**—Yield = 45%; mp = 247–250°C dec. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 3.87 (s, 3H, OCH<sub>3</sub>), 6.50 (d, 1H, Ar, *J* = 1.6 Hz), 7.18 (dd, 1H, Ar, *J* = 2.4 Hz and *J* = 8.4 Hz), 7.33 (s, 1H, Ar), 7.50 (d, 1H, Ar, *J* = 2.4 Hz), 7.82–7.90 (m, 3H, Ar), 8.16 (d, 1H, Ar, *J* = 4.0 Hz), 8.29 (d, 1H, Ar, *J* = 3.6 Hz), 8.62 (d, 1H, Ar, *J* = 3.2 Hz), 11.71 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>18</sub>H<sub>14</sub>N<sub>2</sub>O, 274.32; found: *m/z* 275.11 [M+H]<sup>+</sup>. Anal. C<sub>18</sub>H<sub>14</sub>N<sub>2</sub>O (C, H, N).

### General procedure for compounds 11a-f.

A mixture of the appropriate 1H-pyrrolo[2,3-b]pyridine derivative **10a-f** (0.95 mmol) [**10a**, Laha et al., 2017; **10c** and **10d**, Ibrahim et al., 2007; **10f**, Singh et al. 2017] and HMTA (1.43 mmol) in glacial acetic acid (3 mL) was heated under reflux for 6 h. The reaction mixture was cooled at room temperature and diluted with cold water. The solid obtained was filtered, washed with an excess of ice-cold water, and dried. The crude compound was purified by crystallization from hexane (**11b,e**) or by column chromatography using cyclohexane/ethyl acetate 1:3 (for **11a,d**), dichloromethane/methanol 95:5 (for **11c**), or cyclohexane/ethyl acetate 1:5 (for **11f**) as eluents.

**5-Phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (11a).**—Yield = 56%; mp = 212–215°C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 7.42 (t, 1H, Ar, *J* = 7.2 Hz), 7.51 (t, 2H, Ar, *J* = 7.6 Hz),



7.67 (d, 2H, Ar,  $J=7.2$  Hz), 8.10 (s, 1H, Ar), 8.68 (s, 1H, Ar), 8.89 (s, 1H, Ar), 10.08 (s, 1H, CHO), 11.82 (exch br s, 1H, NH). ESI-MS calcd. for  $C_{14}H_{10}N_2O$ , 222.24; found:  $m/z$  223.08  $[M+H]^+$ . Anal.  $C_{14}H_{10}N_2O$  (C, H, N).

**5-(3-(Trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (11b).**

—Yield = 80%; mp = 193–196°C (hexane).  $^1H$ -NMR (DMSO- $d_6$ )  $\delta$  7.23 (d, 2H, Ar,  $J=7.2$  Hz), 8.04 (d, 2H, Ar,  $J=8.4$  Hz), 8.52 (s, 1H, Ar), 8.63 (d, 1H, Ar,  $J=2.0$  Hz), 8.71 (d, 1H, Ar,  $J=2.0$  Hz), 9.45 (s, 1H, CHO), 12.65 (exch br s, 1H, NH). ESI-MS calcd. for  $C_{15}H_9F_3N_2O$ , 290.24; found:  $m/z$  291.07  $[M+H]^+$ . Anal.  $C_{15}H_9F_3N_2O$  (C, H, N).

**5-(m-Tolyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (11c).**

—Yield = 62%; mp = 162–165°C.  $^1H$ -NMR (DMSO- $d_6$ )  $\delta$  2.38 (s, 3H,  $CH_3$ ), 7.19 (d, 1H, Ar,  $J=7.6$  Hz), 7.36 (t, 1H, Ar,  $J=7.2$  Hz), 7.48 (d, 1H, Ar,  $J=7.6$  Hz), 7.52 (s, 1H, Ar), 8.48 (s, 1H, Ar), 8.55 (d, 1H, Ar,  $J=2.0$  Hz), 8.62 (d, 1H, Ar,  $J=2.0$  Hz), 9.93 (s, 1H, CHO), 12.75 (exch br s, 1H, NH). ESI-MS calcd. for  $C_{15}H_{12}N_2O$ , 236.27; found:  $m/z$  237.10  $[M+H]^+$ . Anal.  $C_{15}H_{12}N_2O$  (C, H, N).

**5-(3-Methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (11d).**

—Yield = 37%; mp = 200–203°C.  $^1H$ -NMR (DMSO- $d_6$ )  $\delta$  3.90 (s, 3H,  $OCH_3$ ), 6.97 (d, 1H, Ar,  $J=8.4$  Hz), 7.17 (s, 1H, Ar), 7.23 (s, 1H, Ar), 7.42 (t, 1H, Ar,  $J=8.0$  Hz), 8.07 (s, 1H, Ar), 8.64 (s, 1H, Ar), 8.92 (s, 1H, Ar), 10.08 (s, 1H, CHO), 12.70 (exch br s, 1H, NH). ESI-MS calcd. for  $C_{15}H_{12}N_2O_2$ , 252.27; found:  $m/z$  253.09  $[M+H]^+$ . Anal.  $C_{15}H_{12}N_2O_2$  (C, H, N).

**5-(6-methoxynaphthalen-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (11e).**

—Yield = 84%; mp = 145–147°C (hexane).  $^1H$ -NMR (DMSO- $d_6$ )  $\delta$  3.88 (s, 3H,  $OCH_3$ ), 7.20 (d, 1H, Ar,  $J=8.8$  Hz), 7.36 (s, 1H, Ar), 7.84–7.95 (m, 3H, Ar), 8.21 (s, 1H, Ar), 8.52 (s, 1H, Ar), 8.69 (s, 1H, Ar), 8.78 (s, 1H, Ar), 9.97 (s, 1H, CHO), 12.57 (exch br s, 1H, NH). ESI-MS calcd. for  $C_{19}H_{14}N_2O_2$ , 302.33; found:  $m/z$  303.11  $[M+H]^+$ . Anal.  $C_{19}H_{14}N_2O_2$  (C, H, N).

**5-(Thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (11f).**

—Yield = 37%; mp = 194–196°C.  $^1H$ -NMR (DMSO- $d_6$ )  $\delta$  7.60–7.66 (m, 2H, Ar), 7.95 (s, 1H, Ar), 8.46 (s, 1H, Ar), 8.60 (s, 1H, Ar), 8.74 (s, 1H, Ar), 9.93 (s, 1H, CHO), 12.71 (exch br s, 1H, NH). ESI-MS calcd. for  $C_{12}H_8N_2OS$ , 228.27; found:  $m/z$  229.04  $[M+H]^+$ . Anal.  $C_{12}H_8N_2OS$  (C, H, N).

**General procedure for compounds 12a-g.**

Compounds **12a-g** were obtained following the same procedure reported for compounds **5a,c**, but starting with intermediates **11a-g** [11g, Ibrahim et al., 2007]. The crude products were purified by crystallization from ethanol (**12c,d,g**) or by column chromatography using cyclohexane/ethyl acetate 1:5 (for **12a,b**), cyclohexane/ethyl acetate 1:2 (for **12e**), or cyclohexane/ethyl acetate 1:3 (for **12f**) as eluents.

**5-Phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (12a).**

—Yield = 42%; mp = 224–226°C.  $^1H$ -NMR (CDCl $_3$ - $d_1$ )  $\delta$  7.40 (d, 1H, Ar,  $J=7.6$  Hz), 7.46–7.52 (m, 3H,

2H Ar + 1H *CH=N-OH*), 7.63 (d, 2H, Ar, *J* = 7.6 Hz), 8.33 (s, 1H, Ar), 8.59 (s, 1H, Ar), 8.69 (s, 1H, Ar), 10.31 (exch br s, 1H, *CH=N-OH*), 11.95 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>14</sub>H<sub>11</sub>N<sub>3</sub>O, 237.26; found: *m/z* 238.09 [M+H]<sup>+</sup>. Anal. C<sub>14</sub>H<sub>11</sub>N<sub>3</sub>O (C, H, N).

**5-(3-(Trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (12b).**—Yield = 52%; mp = 247–250°C. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 7.72 (d, 3H, Ar, *J* = 4.0 Hz), 7.82 (s, 1H, *CH=N-OH*), 7.96 (s, 1H, Ar), 8.28 (s, 1H, Ar), 8.51 (d, 1H, Ar, *J* = 2.0 Hz), 8.64 (d, 1H, Ar, *J* = 1.6 Hz), 10.74 (exch br s, 1H, *CH=N-OH*), 12.10 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>15</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O, 305.25; found: *m/z* 306.08 [M+H]<sup>+</sup>. Anal. C<sub>15</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O (C, H, N).

**5-(*m*-Tolyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (12c).**—Yield = 51%; mp = 208–211°C (EtOH). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 2.37 (s, 3H, CH<sub>3</sub>), 7.16 (s, 1H, *CH=N-OH*), 7.35 (t, 1H, Ar, *J* = 7.6 Hz), 7.44 (t, 1H, Ar, *J* = 7.6 Hz), 7.50–7.56 (m, 1H, Ar), 7.78 (d, 1H, Ar, *J* = 2.0 Hz), 8.25–8.30 (m, 1H, Ar), 8.46 (d, 1H, Ar, *J* = 2.0 Hz), 8.54–8.59 (m, 1H, Ar), 10.71 (exch br s, 1H, *CH=N-OH*), 12.00 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O, 251.28; found: *m/z* 252.11 [M+H]<sup>+</sup>. Anal. C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O (C, H, N).

**5-(3-Methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (12d).**—Yield = 84%; mp = 191–194°C (EtOH). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 3.81 (s, 3H, OCH<sub>3</sub>), 6.91–6.96 (m, 1H, Ar), 7.17–7.22 (m, 2H, Ar), 7.35–7.40 (m, 2H, 1H Ar + 1H *CH=N-OH*), 7.78 (s, 1H, Ar), 8.26 (s, 1H, Ar), 8.64 (s, 1H, Ar), 10.72 (exch br s, 1H, *CH=N-OH*), 12.03 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>, 267.28; found: *m/z* 268.10 [M+H]<sup>+</sup>. Anal. C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> (C, H, N).

**5-(6-Methoxynaphthalen-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (12e).**—Yield = 37%; mp = 204–207°C dec. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 3.88 (s, 3H, OCH<sub>3</sub>), 7.19 (d, 1H, Ar, *J* = 8.4 Hz), 7.35 (s, 1H, Ar), 7.74–7.79 (m, 1H, Ar), 7.89–7.94 (m, 3H, Ar), 8.12 (s, 1H, *CH=N-OH*), 8.29 (d, 1H, Ar, *J* = 6.8 Hz), 8.57 (s, 1H, Ar), 8.66–8.71 (m, 1H, Ar), 10.73 (exch br s, 1H, *CH=N-OH*), 12.01 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>, 317.34; found: *m/z* 318.12 [M+H]<sup>+</sup>. Anal. C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> (C, H, N).

**5-(Thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (12f).**—Yield = 54%; mp = 239–242°C. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 7.50 (d, 1H, Ar, *J* = 4.8 Hz), 7.66 (s, 1H, Ar), 7.77 (d, 1H, Ar, *J* = 7.6 Hz), 8.25 (s, 1H, *CH=N-OH*), 8.45 (s, 1H, Ar), 8.62–8.67 (m, 2H, Ar), 10.71 (exch br s, 1H, *CH=N-OH*), 11.99 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>OS, 243.28; found: *m/z* 244.05 [M+H]<sup>+</sup>. Anal. C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>OS (C, H, N).

**5-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde oxime (12g).**—Yield = 67%; mp = 241–243°C (EtOH). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 7.50 (d, 1H, Ar, *J* = 4.8 Hz), 7.79 (s, 1H, Ar), 8.07 (d, 1H, Ar, *J* = 6.4 Hz), 8.27 (s, 1H, *CH=N-OH*), 8.49–8.65 (m, 3H, Ar), 8.81 (s, 1H, Ar), 10.74 (exch br s, 1H, *CH=N-OH*), 12.10 (exch br s, 1H, NH). ESI-MS calcd. for C<sub>13</sub>H<sub>10</sub>N<sub>4</sub>O, 238.24; found: *m/z* 239.09 [M+H]<sup>+</sup>. Anal. C<sub>13</sub>H<sub>10</sub>N<sub>4</sub>O (C, H, N).

**General procedure for compounds 13a-g.**

Compounds **13a-g** were obtained following the same procedure reported for compounds **6b,c**, but starting with intermediates **12a-g**. The crude products were purified by crystallization from ethanol.

**5-Phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (13a).**—Yield = 40%; mp = 199–202°C (EtOH). <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 7.47 (d, 1H, Ar, *J* = 7.2 Hz), 7.53 (t, 2H, Ar, *J* = 7.2 Hz), 7.63 (d, 2H, Ar, *J* = 7.6 Hz), 7.97 (s, 1H, Ar), 8.48 (s, 1H, Ar), 8.71 (s, 1H, Ar), 12.65 (exch br s, 1H, NH). IR ν (cm<sup>-1</sup>): 2220 (CN). ESI-MS calcd. for C<sub>14</sub>H<sub>9</sub>N<sub>3</sub>, 219.24; found: *m/z* 220.08 [M+H]<sup>+</sup>. Anal. C<sub>14</sub>H<sub>9</sub>N<sub>3</sub> (C, H, N).

**5-(3-(Trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (13b).**—Yield = 85%; mp = 240–242°C (EtOH). <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 7.70 (t, 1H, Ar, *J* = 7.6 Hz), 7.76 (d, 1H, Ar, *J* = 7.6 Hz), 7.82 (d, 1H, Ar, *J* = 7.6 Hz), 7.88 (s, 1H, Ar), 8.09 (s, 1H, Ar), 8.62 (s, 1H, Ar), 8.71 (s, 1H, Ar), 12.75 (exch br s, 1H, NH). IR ν (cm<sup>-1</sup>): 2222 (CN). ESI-MS calcd. for C<sub>15</sub>H<sub>8</sub>F<sub>3</sub>N<sub>3</sub>, 287.24; found: *m/z* 288.07 [M+H]<sup>+</sup>. Anal. C<sub>15</sub>H<sub>8</sub>F<sub>3</sub>N<sub>3</sub> (C, H, N).

**5-(m-Tolyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (13c).**—Yield = 74%; mp = 194–197°C (EtOH). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 2.38 (s, 3H, CH<sub>3</sub>), 7.19 (d, 1H, Ar, *J* = 7.6 Hz), 7.36 (t, 1H, Ar, *J* = 7.6 Hz), 7.55 (d, 1H, Ar, *J* = 7.6 Hz), 7.61 (s, 1H, Ar), 8.29 (d, 1H, Ar, *J* = 1.6 Hz), 8.46 (d, 1H, Ar, *J* = 2.4 Hz), 8.67 (d, 1H, Ar, *J* = 2.0 Hz), 12.87 (exch br s, 1H, NH). IR ν (cm<sup>-1</sup>): 2220 (CN). ESI-MS calcd. for C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>, 233.27; found: *m/z* 234.10 [M+H]<sup>+</sup>. Anal. C<sub>15</sub>H<sub>11</sub>N<sub>3</sub> (C, H, N).

**5-(3-Methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (13d).**—Yield = 94%; mp = 201–204°C (EtOH). <sup>1</sup>H-NMR (CDCl<sub>3</sub>-d<sub>1</sub>) δ 3.83 (s, 3H, OCH<sub>3</sub>), 6.94 (d, 1H, Ar, *J* = 7.6 Hz), 7.30–7.35 (m, 2H, Ar), 7.38 (t, 1H, Ar, *J* = 7.2 Hz), 8.33 (d, 1H, Ar, *J* = 1.6 Hz), 8.47 (s, 1H, Ar), 8.69 (d, 1H, Ar, *J* = 1.6 Hz), 12.91 (exch br s, 1H, NH). IR ν (cm<sup>-1</sup>): 2220 (CN). ESI-MS calcd. for C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O, 249.27; found: *m/z* 250.09 [M+H]<sup>+</sup>. Anal. C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O (C, H, N).

**5-(6-Methoxynaphthalen-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (13e).**—Yield = 63%; mp = 193–196°C (EtOH). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 3.88 (s, 3H, OCH<sub>3</sub>), 7.14–7.19 (m, 1H, Ar), 7.35 (s, 1H, Ar), 7.91–7.99 (m, 3H, Ar), 8.28 (s, 1H, Ar), 8.43–8.50 (m, 2H, Ar), 8.82 (s, 1H, Ar), 12.89 (exch br s, 1H, NH). IR ν (cm<sup>-1</sup>): 2221 (CN). ESI-MS calcd. for C<sub>19</sub>H<sub>13</sub>N<sub>3</sub>O, 299.33; found: *m/z* 300.11 [M+H]<sup>+</sup>. Anal. C<sub>19</sub>H<sub>13</sub>N<sub>3</sub>O (C, H, N).

**5-(thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (13f).**—Yield = 88%; mp = 165–167°C (EtOH). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 7.67–7.73 (m, 2H, Ar), 8.05 (s, 1H, Ar), 8.39–8.44 (m, 2H, Ar), 8.80 (s, 1H, Ar), 12.86 (exch br s, 1H, NH). IR ν (cm<sup>-1</sup>): 2222 (CN). ESI-MS calcd. for C<sub>12</sub>H<sub>7</sub>N<sub>3</sub>S, 225.27; found: *m/z* 226.04 [M+H]<sup>+</sup>. Anal. C<sub>12</sub>H<sub>7</sub>N<sub>3</sub>S (C, H, N).

**5-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (13g).**—Yield = 71%; mp = 285–287°C dec (EtOH). (DMSO-d<sub>6</sub>) δ 7.44–7.49 (m, 1H, Ar), 8.18 (d, 1H, Ar, *J* = 6.0 Hz), 8.40 (s, 1H, Ar), 8.47 (s, 1H, Ar), 8.57 (s, 1H, Ar), 8.73 (s, 1H, Ar), 8.97 (s, 1H, Ar),

12.96 (exch br s, 1H, NH). IR  $\nu$  ( $\text{cm}^{-1}$ ): 2220 (CN). ESI-MS calcd. for  $\text{C}_{13}\text{H}_8\text{N}_4$ , 220.23; found:  $m/z$  221.08  $[\text{M}+\text{H}]^+$ . Anal.  $\text{C}_{13}\text{H}_8\text{N}_4$  (C, H, N).

### General procedure for compounds 14a-g.

Compounds **14a-g** were obtained following the same procedure reported for compounds **7a-c**, but starting with intermediates **13a-g**. The crude products were purified by column chromatography using cyclohexane/ethyl acetate 5:1 (for **14a-e**), cyclohexane/ethyl acetate 4:1 (for **14f**), or cyclohexane/ethyl acetate 1:3 (for **14g**) as eluents.

#### 1-(3-Methylbenzoyl)-5-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (14a).—

Yield = 17%; mp = 160–163°C.  $^1\text{H-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  2.45 (s, 3H, m- $\text{CH}_3\text{-Ph}$ ), 7.40–7.45 (m, 2H, Ar), 7.51 (t, 3H, Ar,  $J=7.2$  Hz), 7.61 (t, 3H, Ar,  $J=7.6$  Hz), 7.68 (s, 1H, Ar), 8.24 (s, 1H, Ar), 8.26 (d, 1H, Ar,  $J=2.0$  Hz), 8.68 (d, 1H, Ar,  $J=2.0$  Hz).  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  20.93 ( $\text{CH}_3$ ), 101.18 (C), 115.32 (C), 123.82 (CH), 127.54 (CH), 128.17 (CH), 130.86 (CH), 134.56 (CH), 136.41 (C), 138.83 (C), 144.65 (C), 167.76 (CO). IR  $\nu$  ( $\text{cm}^{-1}$ ): 2220 (CN). ESI-MS calcd. for  $\text{C}_{22}\text{H}_{15}\text{N}_3\text{O}$ , 337.37; found:  $m/z$  338.12  $[\text{M}+\text{H}]^+$ . Anal.  $\text{C}_{22}\text{H}_{15}\text{N}_3\text{O}$  (C, H, N).

#### 1-(3-Methylbenzoyl)-5-(3-(trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (14b).—

Yield = 10%; mp = 155–157°C.  $^1\text{H-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  2.46 (s, 3H, m- $\text{CH}_3\text{-Ph}$ ), 7.43 (t, 1H, Ar,  $J=7.6$  Hz), 7.52 (d, 1H, Ar,  $J=8.0$  Hz), 7.58–7.71 (m, 4H, Ar), 7.80 (d, 1H, Ar,  $J=7.6$  Hz), 7.85 (s, 1H, Ar), 8.28 (s, 2H, Ar), 8.67 (d, 1H, Ar,  $J=2.0$  Hz).  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  21.31 ( $\text{CH}_3$ ), 103.41 (C), 115.62 (C), 121.42 (CH), 124.75 (CH), 125.18 (CH), 126.74 (CH), 128.96 (CH), 129.56 (CH), 130.48 (CH), 130.92 (CH), 136.72 (C), 138.92 (C), 144.67 (C), 167.48 (CO). IR  $\nu$  ( $\text{cm}^{-1}$ ): 2220 (CN). ESI-MS calcd. for  $\text{C}_{23}\text{H}_{14}\text{F}_3\text{N}_3\text{O}$ , 405.37; found:  $m/z$  406.11  $[\text{M}+\text{H}]^+$ . Anal.  $\text{C}_{23}\text{H}_{14}\text{F}_3\text{N}_3\text{O}$  (C, H, N).

#### 1-(3-Methylbenzoyl)-5-(m-tolyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (14c).—

Yield = 10%; mp = 115–118°C.  $^1\text{H-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  2.45 (s, 6H, 2 x m- $\text{CH}_3\text{-Ph}$ ), 7.24 (s, 1H, Ar), 7.38–7.43 (m, 4H, Ar), 7.51 (d, 1H, Ar,  $J=7.2$  Hz), 7.59 (d, 1H, Ar,  $J=7.2$  Hz), 7.67 (s, 1H, Ar), 8.23 (s, 1H, Ar), 8.25 (d, 1H, Ar,  $J=2.0$  Hz), 8.67 (d, 1H, Ar,  $J=2.0$  Hz).  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  21.39 ( $\text{CH}_3$ ), 21.56 ( $\text{CH}_3$ ), 90.72 (C), 113.51 (C), 121.17 (C), 124.55 (CH), 126.66 (CH), 127.26 (CH), 127.83 (CH), 128.22 (CH), 128.45 (CH), 129.06 (CH), 129.18 (CH), 131.03 (CH), 132.07 (C), 134.31 (CH), 134.88 (CH), 137.30 (C), 138.75 (C), 139.03 (C), 146.04 (CH), 146.35 (C), 166.72 (CO). IR  $\nu$  ( $\text{cm}^{-1}$ ): 2220 (CN). ESI-MS calcd. for  $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}$ , 351.40; found:  $m/z$  352.14  $[\text{M}+\text{H}]^+$ . Anal.  $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}$  (C, H, N).

#### 5-(3-Methoxyphenyl)-1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (14d).—

Yield = 10%; mp = 152–155°C.  $^1\text{H-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  2.45 (s, 3H, m- $\text{CH}_3\text{-Ph}$ ), 3.88 (s, 3H,  $\text{OCH}_3$ ), 6.97 (d, 1H, Ar,  $J=8.0$  Hz), 7.13–7.20 (m, 2H, Ar), 7.41 (d, 2H, Ar,  $J=7.6$  Hz), 7.51 (d, 1H, Ar,  $J=7.2$  Hz), 7.60 (d, 1H, Ar,  $J=7.2$  Hz), 7.67 (s, 1H, Ar), 8.25 (d, 2H, Ar,  $J=7.6$  Hz), 8.67 (s, 1H, Ar).  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3\text{-d}_1$ )  $\delta$  21.18 ( $\text{CH}_3$ ), 55.76 ( $\text{CH}_3$ ), 102.47 (C), 113.48 (CH), 114.39 (CH), 115.49 (C), 119.82 (CH), 121.43 (C), 123.64 (CH), 126.12 (CH), 128.17 (CH), 129.32 (CH), 130.14 (CH), 131.18 (C), 134.56 (CH), 138.97 (C), 144.65 (C), 161.18 (C), 168.71 (CO). IR  $\nu$  ( $\text{cm}^{-1}$ ): 2220 (CN).

ESI-MS calcd. for  $C_{23}H_{17}N_3O_2$ , 367.40; found:  $m/z$  368.14  $[M+H]^+$ . Anal.  $C_{23}H_{17}N_3O_2$  (C, H, N).

**5-(6-Methoxynaphthalen-2-yl)-1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (14e).**—Yield = 22%; oil.  $^1H$ -NMR ( $CDCl_3-d_1$ )  $\delta$  2.46 (s, 3H, m- $CH_3$ -Ph), 3.95 (s, 3H,  $OCH_3$ ), 7.18–7.25 (m, 2H, Ar), 7.43 (t, 1H, Ar,  $J=7.6$  Hz), 7.51 (d, 1H, Ar,  $J=7.2$  Hz), 7.61 (d, 1H, Ar,  $J=7.2$  Hz), 7.68–7.73 (m, 2H, Ar), 7.81–7.88 (m, 2H, Ar), 8.00 (s, 1H, Ar), 8.25 (s, 1H, Ar), 8.36 (s, 1H, Ar), 8.79 (s, 1H, Ar).  $^{13}C$ -NMR ( $CDCl_3-d_1$ )  $\delta$  21.19 ( $CH_3$ ), 55.85 ( $CH_3$ ), 101.06 (C), 105.92 (CH), 113.49 (CH), 114.39 (C), 115.41 (C), 119.87 (CH), 121.43 (C), 123.68 (CH), 125.44 (CH), 126.15 (CH), 128.17 (CH), 129.35 (CH), 129.60 (CH), 130.14 (CH), 131.11 (C), 134.56 (CH), 134.82 (C), 138.91 (C), 144.62 (C), 157.28 (C), 167.70 (CO). IR  $\nu$  ( $cm^{-1}$ ): 2220 (CN). ESI-MS calcd. for  $C_{27}H_{19}N_3O_2$ , 417.46; found:  $m/z$  418.15  $[M+H]^+$ . Anal.  $C_{27}H_{19}N_3O_2$  (C, H, N).

**1-(3-methylbenzoyl)-5-(thiophen-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (14f).**—Yield = 40%; mp = 171–173°C.  $^1H$ -NMR ( $CDCl_3-d_1$ )  $\delta$  2.45 (s, 3H, m- $CH_3$ -Ph), 7.42 (d, 2H, Ar,  $J=7.2$  Hz), 7.47–7.52 (m, 2H, Ar), 7.54–7.59 (m, 2H, Ar), 7.66 (s, 1H, Ar), 8.22 (s, 1H, Ar), 8.25 (d, 1H, Ar,  $J=2.0$  Hz), 8.71 (d, 1H, Ar,  $J=2.0$  Hz).  $^{13}C$ -NMR ( $CDCl_3-d_1$ )  $\delta$  21.35 ( $CH_3$ ), 90.66 (C), 113.42 (C), 121.22 (C), 121.75 (CH), 125.68 (CH), 126.07 (CH), 127.36 (CH), 127.80 (CH), 128.41 (CH), 129.05 (C), 130.99 (CH), 132.08 (C), 132.08 (CH), 135.33 (CH), 138.25 (C), 138.72 (C), 145.36 (CH), 146.09 (C), 166.64 (CO). IR  $\nu$  ( $cm^{-1}$ ): 2222 (CN). ESI-MS calcd. for  $C_{20}H_{13}N_3OS$ , 343.40; found:  $m/z$  344.08  $[M+H]^+$ . Anal.  $C_{20}H_{13}N_3OS$  (C, H, N).

**1-(3-methylbenzoyl)-5-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (14g).**—Yield = 32%; mp = 155–157°C.  $^1H$ -NMR ( $CDCl_3-d_1$ )  $\delta$  2.44 (s, 3H, m- $CH_3$ -Ph), 7.40–7.67 (m, 5H, Ar), 7.93 (d, 1H, Ar,  $J=6.0$  Hz), 8.27 (s, 2H, Ar), 8.67 (d, 2H, Ar,  $J=7.6$  Hz), 8.88 (s, 1H, Ar).  $^{13}C$ -NMR ( $CDCl_3-d_1$ )  $\delta$  21.32 ( $CH_3$ ), 90.71 (C), 113.22 (C), 121.28 (C), 123.57 (CH), 126.84 (CH), 126.98 (CH), 127.85 (CH), 128.47 (CH), 130.83 (C), 131.02 (CH), 131.92 (C), 133.19 (C), 134.83 (CH), 135.02 (CH), 138.81 (C), 145.54 (CH), 145.77 (CH), 146.76 (C), 149.27 (CH), 166.56 (CO). IR  $\nu$  ( $cm^{-1}$ ): 2220 (CN). ESI-MS calcd. for  $C_{21}H_{14}N_4O$ , 338.36; found:  $m/z$  339.12  $[M+H]^+$ . Anal.  $C_{21}H_{14}N_4O$  (C, H, N).

## Pharmacology

Compounds were dissolved in 100% DMSO at 5 mM stock concentrations. The final concentration of DMSO in the reactions was 1%, and this level of DMSO had no effect on HNE activity. The HNE inhibition assay was performed in black flat-bottom 96-well microtiter plates. Briefly, a buffer solution containing 200 mM Tris-HCl, pH 7.5, 0.01% bovine serum albumin, 0.05% Tween-20, and 20 mU/mL HNE (Calbiochem) was added to wells containing different concentrations of each compound. The reactions were initiated by addition of 25  $\mu$ M elastase substrate (N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin, Calbiochem) in a final reaction volume of 100  $\mu$ L/well. Kinetic measurements were obtained every 30 s for 10 min at 25 °C using a Fluoroskan Ascent FL fluorescence microplate reader (Thermo Electron, MA) with excitation and emission wavelengths at 355 and 460 nm, respectively. For all compounds tested, the concentration of

inhibitor that caused 50% inhibition of the enzymatic reaction ( $IC_{50}$ ) was calculated by plotting % inhibition versus logarithm of inhibitor concentration (at least six points). The data are presented as the mean values of at least three independent experiments with relative standard deviations of <15%.

## Molecular modeling

## RESULTS AND DISCUSSION

All new products were tested for their ability to inhibit HNE, and the experiments were conducted in triplicate using *N*-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-cumarin as the substrate. The results are reported in the Tables 1–2 and are compared with the Sivelestat and 1-(3-methylbenzoyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (compound **X**), which we previously found to be a potent HNE inhibitor [Crocetti et al., 2018]. As shown in Table 1, the introduction of substituents at position 2 of the pyrrolo[2,3-b]pyridine scaffold was not favorable for HNE inhibitory activity. In fact, introduction of an alkyl group (compounds **2a** and **2b**) or a carbethoxy group (**2c**) led to products completely devoid of activity. In addition, shift of the carbonitrile group from position 3 of compound **X** to position 2 (**2d**) also led to a significant loss in HNE inhibitory activity (two orders of magnitude lower). Likewise, the introduction of a methyl group at position 2 of compound **X** was detrimental for activity, resulting in **2e** with an  $IC_{50}$  of 10.8  $\mu$ M, further confirming that substituents at position 2 are not tolerated without significant loss in HNE inhibitory activity.

In contrast, position 5 was more tolerant to substitutions, as most of the 5-substituted pyrrolo[2,3-b]pyridines exhibited  $IC_{50}$  values in the nanomolar range (0.015–0.070  $\mu$ M) (see Table 2). The 5-bromine derivative was about 3-fold more potent (**7a**,  $IC_{50}$ = 0.051  $\mu$ M) than the 5-chloro (**7b**,  $IC_{50}$ = 0.160  $\mu$ M) derivative, suggesting that lipophilicity ( $\pi$  = 0.86 for Br and 0.71 for Cl), steric bulk ( $Mr$  = 8.88 for Br and 6.03 for Cl), or electron withdrawing ability could be important requirements for activity. On the other hand, the introduction of a nitro group (**7c**), which has an intermediate  $Mr$  between bromine and chlorine ( $Mr$  = 7.36) but hydrophilic properties ( $\pi$  = -0.28) was about 2-fold less potent than the 5-chloro derivative **7b** ( $IC_{50}$ = 0.400 and 0.160  $\mu$ M, respectively).

Insertion of bulky and lipophilic rings was favorable for HNE inhibitory activity within certain limits, as demonstrated by the comparable potency of the 5-(substituted)phenyl derivatives **14a-d** ( $IC_{50}$ = 0.050–0.180  $\mu$ M) and the low activity of compound **14e** bearing a 6-OCH<sub>3</sub>-naphthalen at position 5 ( $IC_{50}$ = 1.6  $\mu$ M). Replacement of the phenyl at position 5 in compound **14a** with the isostere thienyl or pyridyl rings resulted in the thienyl derivative **14f** with comparable potency to **14a** ( $IC_{50}$ = 0.042 versus 0.050  $\mu$ M, respectively) and the pyridyl derivative **14g**, which was about 3-fold more potent than **14a** ( $IC_{50}$ = 0.015 versus 0.050  $\mu$ M, respectively). Thus, the presence of pyridine in compound **14g** may be important not only for steric hindrance but also for the formation of an H-bond that involves a nitrogen atom, which is not found in **14a**.

Taking into account these biological results and in particular the observation that the most potent 5-substituted compound (**14g**) exhibited the same  $IC_{50}$  as the 5-unsubstituted lead compound **X**, we can conclude that the introduction of certain substituents at position 5

maintained HNE inhibitory activity, probably by interacting with the large pocket of the enzyme site. On the other hand, we were not able to improve the HNE inhibitory activity with respect to the lead **X**.

The difference in activities of the test compounds can be explained by the length  $L$  of the proton transfer channel, angle  $\alpha$ , and length  $d_1$ . As reported previously, a nitrogen atom in the six-membered pyridine moiety of the lead **X** forms an H-bond with Asp194 [Crocetti et al., 2018]. Additional H-bonding occurs with Val216 due to the nitrogen atom of the cyano group in lead compound **X** [Crocetti et al., 2018]. The distance  $d_1$  for molecule **X** is smaller than for other active compounds in Table 3. In general, the geometry of the inhibitor-enzyme complex is favorable for the formation of a Michaelis complex when the oxygen atom of Ser195 attacks the carbonyl carbon atom of compound **X**.

Although compound **2e** has distance  $d_1$  and angle  $\alpha$  suitable for inhibitory activity, arrangement of the amino acid residues of the key triad Ser195-His57-Asp102 becomes unfavorable because the length  $L$  of the proton transfer channel is greatly increased (Table 3), which may be the main reason for the low inhibitory activity of compound **2e**, despite the formation of H-bonds with Ser195 and Gly193 involving two nitrogen atoms (Figure 5A). Although compound **2d** has a short length  $L$ , it has strong anchoring due to H-bonding of the carbonyl oxygen with Ser195 of the catalytic triad (not shown). Clearly, significant fixation of the molecule at the binding site leads to unfavorable activity (i.e., angle  $\alpha$  is too acute for compound **2d**, see Table 3). This may cause difficulties in formation of the Michaelis complex and, therefore, reduced activity of **2d**. It should be noted that the cyano group at position 2 does not form H-bonds with the enzyme, in contrast with the same group at position 3 of molecule **X**.

As for the highly active HNE inhibitors **14c** and **14g**, the geometric parameters of the docking poses, as well as the distance  $L$ , were favorable for the formation of Michaelis complexes and for proton transfer via the catalytic triad (Table 3). It should be noted that the angle  $\alpha$  for compound **14c** falls slightly out of the optimal interval 80–120° [Groutas et al., 1997; Vergely et al., 1996], which can explain the reduced inhibitory activity in comparison with inhibitor **14g**. Molecules **14c** and **14g** are fixed within the HNE binding site by H-bonds in the above-mentioned orientations that are favorable for biological activity (Figure 5B). Thus, the geometrical parameters of the docking poses found with flexible side chains of the enzyme allow us to explain the differences in inhibitory activity of the investigated compounds.

## CONCLUSIONS

In the present study, we further investigated the pyrrolo[2,3-b]pyridine scaffold, which was previously found to be suitable for the synthesis of HNE inhibitors ( $IC_{50}$ =14–87 nM) [Crocetti et al., 2018]. While maintaining the best substituents identified for N-1 and position 3 (m-toluoyl and CN groups, respectively), we introduced substituents with different features at position 5 in order to assess the impact of these modifications on binding and HNE inhibition. Moreover, we also evaluated modification of the substituent at position 2 of the scaffold. The biological results clearly demonstrated that position 2 of the

pyrrolo[2,3-b]pyridine scaffold must be unsubstituted, whereas the introduction of certain substituents at position 5 maintained HNE inhibitory activity comparable with that of reference compound X, probably by interacting with the large pocket of the enzyme site. According to our molecular modeling, the most active HNE inhibitors bind the enzyme in conformations suitable for the formation of a Michaelis complex between the ligand C=O group and Ser195. Additionally, for the potent inhibitors, a mutual orientation of the ligand with the catalytic triad is necessary for effective proton transfer from the oxyanion hole.

## ACKNOWLEDGEMENTS

This research was supported in part by National Institutes of Health IDeA Program COBRE Grant GM110732; USDA National Institute of Food and Agriculture Hatch project 1009546; Montana University System Research Initiative: 51040-MUSRI2015-03; Tomsk Polytechnic University Competitiveness Enhancement Program; Ministry of Education and Science of the Russian Federation project No. 4.8192.2017/8.9, and the Montana State University Agricultural Experiment Station.


## REFERENCES

- Bahekar RH, Jain MR, Jadavav PA, Projapati VM, Patel DN, Gupta AA, Sharma A, Tom R, Bandyopadhyaya D, Modi H. 2007 Synthesis and antidiabetic activity of 2,5-disubstituted-3-imidazol-2-yl-pyrrolo[2,3-b]pyridines. *Bioorg Med Chem* 15(21):6782–6795. [PubMed: 17723306]
- Baltus CB, Jorda R, Marat C, Berka C, Bazgier V, Krystal V, Priè G, Viad-Massuard MC. 2016 Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/ cyclin E inhibitors. *Eur J Med Chem* 108:701–719. [PubMed: 26741853]
- Bhat PV, Dere RT, Ravikumar S, Hindupur RM, Pati HN. 2015 Efficient and Scalable Process for Synthesis of 5-Nitro-7-azaindole. *Org Process Res Dev* 19:1282–1285.
- Chen G, Ren H, Zhang N, Lennox W, Turpoff A, Paget S, Li C, Almstead N, Njoroge FG, Gu Z. 2015 (Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B. *Bioorg Med Chem Lett* 25:781–786. [PubMed: 25613678]
- Crocetti L, Giovannoni MP, Schepetkin IA, Quinn MT, Khlebnikov AI, Cilibrizzi A, Dal Piaz V, Graziano A, Vergelli C. 2011 Design, synthesis and evaluation of N-benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase. *Bioorg Med Chem* 19:4460–4472. [PubMed: 21741848]
- Crocetti L, Schepetkin IA, Ciciani G, Giovannoni MP, Guerrini G, Iacovone A, Khlebnikov AI, Kirpotina LN, Quinn MT, Vergelli C. 2016 Synthesis and pharmacological evaluation of indole derivatives as deaza analogues of potent human neutrophil elastase inhibitors. *Drug Dev Res* 77 (6): 285–289. [PubMed: 27474878]
- Crocetti L, Schepetkin IA, Cilibrizzi A, Graziano A, Vergelli C, Giomi D, Khlebnikov AI, Quinn MT, Giovannoni MP. 2013 Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase. *J Med Chem* 56:6259–6272. [PubMed: 23844670]
- Crocetti L, Giovannoni MP, Schepetkin IA, Quinn MT, Khlebnikov AI, Cantini N, Guerrini G, Iacovone A, Teodori E, Vergelli C. 2018 1H-pyrrolo[2,3-b]pyridine: A new scaffold for human neutrophil elastase (HNE) inhibitor. *Bioorg Med Chem* doi.org/10.1016/j.bmc.2018.09.034.
- Ermoli A, Bargiotti A, Brasca MG, Ciavoletta A, Colombo N, Fachin G, Isacchi A, Menichincheri M, Molinari A, Montagnoli A, Pillan A, Rainoldi S, Sirtori FR, Sola F, Thieffine S, Tibolla M, Valsasina B, Volpi D, Santocanale C, Vanotti E. 2009 Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships. *Med Chem* 52:4380–4390.
- Fujinaga M, Chernaiaa MM, Halenbeck R, Koths K, James MNG. 1996 The Crystal Structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. *J Mol Biol* 261:267–278. [PubMed: 8757293]
- Giovannoni MP, Schepetkin IA, Crocetti L, Ciciani G, Cilibrizzi A, Guerrini G, Khelebnikov AI, Quinn MI, Vergelli C. 2016 Cinnoline derivatives as human neutrophil elastase inhibitors. *J Enz Inhib Med Chem* 31(4):628–639.




- Giovannoni MP, Schepetkin IA, Quinn MT, Cantini N, Crocetti L, Guerrini G, Iacovone A, Paoli P, Rossi P, Bartolucci G, Menicatti M, Vergelli C. 2018 Synthesis, biological evaluation, and molecular modelling studies of potent human neutrophil elastase (HNE) inhibitors. *J Enz Inhib Med Chem* 33(1):1108–1124.
- Graczyk P, Palmer V, Khan A. 2004 Preparation of 3-ethynyl or 3-cyano-1H-pyrrolo[2,3-b]pyridine derivatives as c-Jun N-terminal kinase (JNK) inhibitors. From PCT Int Appl WO 2004101565.
- Groutas WC, Kuang R, Venkataraman R, Epp JB, Ruan S, Prakash O. 1997 Structure-based design of a general class of mechanism-based inhibitors of the serine proteinases employing a novel amino acid-derived heterocyclic scaffold. *Biochemistry* 36:4739–4750. [PubMed: 9125494]
- Ibrahim PN, Artis DR, Bremer R, Habets G, Mamo S, Nespi M, Zhang C, Zhang J, Zhu Y-L, Zuckerman R, Krupka H, Kumar A, West B. 2007 Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. From PCT Int Appl WO 2007002433.
- Joydev KL, Rohan AB, Mandeep Kaur H. 2017 Intramolecular oxidative arylations in 7-azaindoles and pyrroles: revamping the synthesis of fused N-heterocycle tethered fluorenes. *Chem Europ J* 23:2044–2050.
- Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. 2010 Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. *Pharmacol Rev* 62:726–759. [PubMed: 21079042]
- Laha JK, Bhimpuria RA, Hunjan MK. 2017 Intramolecular Oxidative Arylations in 7-Azaindoles and Pyrroles: Revamping the Synthesis of Fused N-Heterocycle Tethered Fluorenes. *Chem Europ J* DOI: 10.1002/chem.201604192.
- Liu N, Wang Y, Huang G, Ji C, Fan W, Li H, Cheng Y, Tian H. 2016 Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors. *Bioorg Chem* 65:146–158. [PubMed: 26950400]
- Lucas SD, Costa E, Guedes RC, Moreira R. 2011 Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase. *Med Res Rev* 33:E73–E101. [PubMed: 21681767]
- Navia MA, McKeever BM, Springer JP, Lin TY, Williams HR, Fluder EM, Dorn CP, Hoogsteen K. 1989 Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84 Å resolution. *Proc Natl Acad Sci USA* 86:7–11. [PubMed: 2911584]
- Nirogi R, Shinde A, Daulatabad A, Kambhampati R, Gudla P, Shaik M, Gampa M, Balasubramian S, Gangadasari P, Reballi V. 2012 Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT<sub>6</sub> Receptor Antagonists. *J Med Chem* 55:9255–9269. [PubMed: 23006002]
- Peters MB, Merz KM. 2006 Semiempirical comparative binding energy analysis (SECOMBINE) of a series of trypsin inhibitors. *J Chem Theory Comput* 2:383–399. [PubMed: 26626526]
- Pham CT. 2006 Neutrophil serine proteases: specific regulators of inflammation. *Nat Rev Immunol* 6:541–550. [PubMed: 16799473]
- Pires MJD, Poeira DL, Purificacao SI, Marques MMB. 2016 Synthesis of substituted 4-, 5-, 6- and 7-azaindoles from aminopyridines via a cascade C-N cross-coupling/Heck Reaction. *Org Lett* 18(13):3250–3253. [PubMed: 27331271]
- Polverino E, Rosales-Mayor E, Dale GE, Dembowski K, Torres A. 2017 The role of Neutrophil Elastase Inhibitors in Lung Diseases. *Chest* 152(2):249–262. [PubMed: 28442313]
- Sandham DA, Adcock C, Bala K, Barker L, Brown Z, Dubois G, Budd D, Cox B, Fairhurst RA, Furegati M, Leblanc C, Manini J, Profit R, Reilly J, Stringer R, Schmidt A, Turner KL, Watson SJ, Willis J, Williams J, Wilson C. 2009 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh<sub>2</sub> receptor antagonists. *Bioorg Med Chem* 19:4794–4798.
- Schepetkin IA, Khlebnikov AI, Quinn MT. 2007 N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. *J Med Chem* 50:4928–4938. [PubMed: 17850059]
- Singh U, Chashoo G, Khan SU, Mahajan P, Singh A, Sharma A, Mintoo MJ, Guru SK, Aruri H, Thatikonda T, Sahu P, Chibber P, Kumar V, Mir SA, Bharate SS, Madishetti S, Nandi U, Singh G, Mondhe DM, Bhushan S, Malik F, Mignani S, Vishwakarma RA, Singh PP. 2017 Design o novel 3-pyrimidinylazaindole CDK2/9 inhibitors with potent in vivo antitumor efficacy in a triple negative breast cancer model. *J Med Chem* 60(23):9470–9489. [PubMed: 29144137]

- Vergelli C, Schepetkin IA, Crocetti L, Iacovone A, Giovannoni MP, Guerrini G, Khlebnikov AI, Ciattini S, Ciciani G, Quinn MT. 2017 Isoxazol-5(2H)-one: a new scaffold for potent human neutrophil elastase (HNE) inhibitors. *J Enz Inhib Med Chem* 32(1):821–831.
- Vergely I, Laugaa P, Reboud-Ravaux M. 1996 Interaction of human leukocyte elastase with a N-aryl azetidinone suicide substrate: conformational analyses based on the mechanism of action of serine proteinases. *J Mol Graph* 14(3):158–167. [PubMed: 8901643]
- Von Nussbaum F, Li VMJ. 2015 Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores. *Bioorg Med Chem Lett* 25:4370–4381. [PubMed: 26358162]
- Von Nussbaum F, Li VMJ, Daniel Meibom D, Anlauf S, Bechem M, Delbeck M, Gerisch M, Harrenga A, Karthaus D, Lang D, Lustig K, Mittendorf J, Schäfer M, Schäfer S, Schamberger J. 2016 Potent and selective human neutrophil elastase inhibitors with novel equatorial ring topology: in vivo efficacy of the polar pyrimidopyridazine BAY-8040 in a pulmonary arterial hypertension rat model. *ChemMedChem* 11:199–206. [PubMed: 26333652]
- Xi N, Li X. 2014 Preparation of alkenyl-pyrrolo[2,3-b]pyridine compounds as protein tyrosine kinase modulators useful for treatment of proliferative disorders. From PCT Int Appl WO 2014193647.
- Zhong QQ, Wang X, Li YF, Peng LJ, Jiang ZS. 2017 Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis. *Exp Biol Med* 242(3):250–257.




**Figure 1.**  
Further modifications of the pyrrolo[2,3-b]pyridine scaffold.

<b>1,2</b>	<b>R<sub>2</sub></b>	<b>R<sub>3</sub></b>
<b>a</b>	CH <sub>3</sub>	H
<b>b</b>	CH <sub>2</sub> CH <sub>3</sub>	H
<b>c</b>	COOEt	H
<b>d</b>	CN	H
<b>e</b>	CH <sub>3</sub>	CN



**Figure 2. Reagents and conditions:**


a) *m*-Toluoyl chloride, Et<sub>3</sub>N, dry DCM, 0°C, 2h; r.t., 2h.




3-7	R <sub>5</sub>
a	Br
b	Cl
c	NO <sub>2</sub>

**Figure 3. Reagents and conditions:**


**a)** HTMA, CH<sub>3</sub>COOH, reflux, 4h; **b)** NH<sub>2</sub>OH·HCl, H<sub>2</sub>O, 60°C, 30 min; NaHCO<sub>3</sub>, reflux, 4h; **c)** POCl<sub>3</sub>, reflux, 1h; **d)** *m*-Toluoyl chloride, NaH, dry THF, r.t., 24h.

**Figure 4. Reagents and conditions:**

**a)** Ph-SO<sub>2</sub>Cl, Et<sub>3</sub>N, dry DCM, 0°C, 2h then r.t., 2h; **b)** R<sub>5</sub>-B(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> 2M, anhydrous toluene, reflux, 4–5h; **c)** TBAF, dry THF, reflux, 2–6h; **d)** HMTA, CH<sub>3</sub>COOH, reflux, 6h; **e)** NH<sub>2</sub>OH·HCl, H<sub>2</sub>O, 60°C, 30 min; NaHCO<sub>3</sub>, 100°C, 4h; **f)** POCl<sub>3</sub>, reflux, 2h; **g)** *m*-Toluoyl chloride, NaH, dry THF, r.t., 24h.



**Figure 5.** Docking poses of inhibitors **2e** and **14g** based on the pyrrolo[2,3-b]pyridine scaffold in the human neutrophil elastase binding site (1HNE entry of Protein Data Bank). **Panel A.** Docking pose of molecule **2e**. Ser195 is H-bonded to amide nitrogen atom, while the cyano group forms a hydrogen bond with Gly193. **Panel B.** Docking pose of molecule **14g**. The carbonyl oxygen atom forms a hydrogen bond with Val216. Residues within 4 Å from each pose are shown.

**Table 1:**HNE inhibitory activity of 1H-pyrrolo[2,3-b]pyridine derivatives **2a-e**.


Compound	R <sub>2</sub>	R <sub>3</sub>	IC <sub>50</sub> (μM) <sup>a</sup>
<b>2a</b>	CH <sub>3</sub>	H	N.A. <sup>b</sup>
<b>2b</b>	CH <sub>2</sub> CH <sub>3</sub>	H	N.A. <sup>b</sup>
<b>2c</b>	COOEt	H	N.A. <sup>b</sup>
<b>2d</b>	CN	H	3.5 ± 1.2
<b>2e</b>	CH <sub>3</sub>	CN	10.8 ± 2.2
<b>X<sup>c</sup></b>	H	CN	0.015 ± 0.004
<b>Sivelestat</b>			0.050 ± 0.020

<sup>a</sup>IC<sub>50</sub> values are presented as the mean ± SD of three independent experiment with a 6 -point dilution series for each experiment.

<sup>b</sup>NA: no inhibitory activity was found at the highest concentration of compound tested (50 μM).

<sup>c</sup>Crocetti et al., 2018.



**Table 2:**HNE inhibitory activity of 1H-pyrrolo[2,3-b]pyridine derivatives **7a-c** and **14a-g**.

Compound	R <sub>5</sub>	IC <sub>50</sub> (μM) <sup>a</sup>
<b>7a</b>	Br	0.051 ± 0.014
<b>7b</b>	Cl	0.16 ± 0.05
<b>7c</b>	NO <sub>2</sub>	0.40 ± 0.11
<b>14a</b>	Ph	0.050 ± 0.02
<b>14b</b>	m-CF <sub>3</sub> Ph	0.18 ± 0.07
<b>14c</b>	m-CH <sub>3</sub> Ph	0.13 ± 0.04
<b>14d</b>	m-OCH <sub>3</sub> Ph	0.070 ± 0.015
<b>14e</b>	6-OCH <sub>3</sub> -naphthalene	1.6 ± 0.33
<b>14f</b>	3-thienyl	0.042 ± 0.015
<b>14g</b>	3-pyridyl	0.015 ± 0.004
X <sup>b</sup>	H	0.015 ± 0.004
<b>Sivelestat</b>	-	0.050 ± 0.020

<sup>a</sup>IC<sub>50</sub> values are presented as the mean ± SD of three independent experiments with a 6 -point dilution series for each experiment.

<sup>b</sup>Crocetti et al., 2018.

**Table 3:**Geometric parameters of the enzyme-inhibitor complexes predicted by molecular docking<sup>a</sup>

Compound	IC <sub>50</sub> (μM)	d <sub>1</sub> (Å)	α (degree)	d <sub>3</sub> (Å)	d <sub>2</sub> (Å)	L (Å) <sup>b</sup>
<b>X<sup>c</sup></b>	0.015	2.601	117.0	3.302	3.218, 4.390	6.520
<b>2d</b>	3.5	3.562	41.1	2.600	2.477, 3.562	5.077
<b>2e</b>	10.8	3.342	117.23	3.535	5.355, 6.141	8.890
<b>14c</b>	0.05	3.084	67.33	2.466	3.964, 5.421	6.430
<b>14g</b>	0.015	4.364	117.9	3.007	4.143, 2.945	5.952

<sup>a</sup>The geometric parameters important for formation of a Michaelis complex in the HNE active site are as reported previously [Crocetti et al., 2011], based on the model of synchronous proton transfer from the oxyanion hole in HNE [Groutas et al., 1997]. According to the docking results, a Michaelis complex with Ser195 is formed with participation of the ester carbonyl group.

<sup>b</sup>Length of the channel for proton transfer calculated as d<sub>3</sub>+min(d<sub>2</sub>).

<sup>c</sup>Crocetti et al., 2018.